Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Seeking Alpha's earnings calendar for a full list of companies due to report....
Cemex (NYSE:CX) +2.9% in Wednesday's trading as Barclays upgrades shares to Overweight from Equal Weight with a $9 price target, citing better cost dynamics and attractive upside potential from current levels. Barclays analyst Benjamin...
Sanofi (NASDAQ:SNY)-owned Genzyme has sued Sarepta Therapeutics (NASDAQ:SRPT) accusing the latter's Duchenne muscular dystrophy therapy Elevidys of violating two of its patents. The patents in question involve technology used to alter viruses so...
The three major U.S. averages on Wednesday added on to their solid gains after Federal Reserve chair Jerome Powell said an interest rate cut "could be on the table as soon as September" if data on inflation and...
Pershing Square USA (NYSE:PSUS), Bill Ackman's closed-end fund, is withdrawing its previously announced initial public offering, it said on Wednesday. While (PSUS) has drawn "enormous" interest among investors, billionaire Ackman questioned whether they would...
Clearway Energy (NYSE:CWEN) +2.2% in Wednesday's trading as Morgan Stanley upgrades shares to Overweight from Equal Weight with a $36 price target, raised from $25, seeing upside to current guidance through 2026 and potential...
Tinder parent Match Group (NASDAQ:MTCH) reported an in-line profit and a revenue beat for its second quarter results, overcoming a challenging operating environment and foreign exchange headwinds, and the company announced job cuts in an effort to...
RBC Capital markets has upgraded Sarepta Therapeutics (NASDAQ:SRPT) to outperform ahead of the launch of its Duchenne muscular dystrophy drug Elevidys. The investment bank noted that Sarepta shares have underperformed “despite a very...
Eni (NYSE:E) wobbles between small gains and losses as RBC Capital upgraded shares to Outperform from Sector Perform with an €18 price target, saying the company is starting to demonstrate value creation in its...
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.Is this happening to you frequently? Please report it on our feedback forum.If you have an ad-blocker enabled you may be blocked from proceeding....
